BMY FINANCIAL STATEMENTS

Bristol-Myers Squibb Company — balance sheet, income statement and cash flow trends

BMYBristol-Myers Squibb Company

🇺🇸 USA · US · Healthcare · Drug Manufacturers - General

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue48.5 B $+1.8%

Gross Profit33.3 B $+18.3%

Operating Income12.4 B $+13.9%

EBITDA13.7 B $-15.2%

Net Income7.3 B $+34.2%

Peer Comparison· Drug Manufacturers - General

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
BMY	1.8%	68.7%	28.4%	15.0%
SAN	3.3%	90.8%	23.4%	22.3%
BAYN	-2.9%	59.3%	7.7%	-4.8%
AZN	9.9%	81.6%	33.7%	17.2%
GRF	0.9%	37.7%	19.3%	5.6%
AZN	9.7%	79.7%	33.8%	17.2%
Industry median	3.3%	70.7%	28.4%	15.0%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
BMY	1.8%	68.7%	28.4%	15.0%
PFE	1.4%	69.3%	26.5%	11.8%
GILD	3.5%	79.4%	48.7%	31.0%
AMGN	9.1%	71.5%	44.8%	20.9%
MRK	2.5%	75.9%	28.6%	13.6%
BIIB	0.4%	69.8%	27.4%	13.9%
Industry median	3.3%	70.7%	28.4%	15.0%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity20.1 B $23%
Current Liabilities19.2 B $22%
Long-term Liabilities47.2 B $55%

Key Figures

YoY change

Total Assets86.5 B $-6.4%

Total Liabilities66.4 B $-11.5%

Total Equity20.1 B $+15.4%

Cash & ST Investments10.5 B $-11.0%

Total Debt44.5 B $-13.2%

Net Debt34.9 B $-13.6%

Peer Comparison· Drug Manufacturers - General

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
BMY	1.42	221.5%	2.47	23.2%
SAN	1.01	27.5%	1.33	56.9%
BAYN	1.06	134.8%	9.19	26.7%
AZN	0.91	71.7%	1.29	41.5%
GRF	2.47	177.2%	6.22	27.2%
AZN	0.91	71.7%	1.28	41.5%
Industry median	1.25	94.3%	1.35	28.4%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
BMY	1.42	221.5%	2.47	23.2%
PFE	1.25	71.5%	3.07	43.4%
GILD	1.97	94.3%	0.85	41.8%
AMGN	1.26	623.8%	2.71	9.9%
MRK	1.30	107.1%	2.31	35.7%
BIIB	3.06	35.2%	0.84	63.3%
Industry median	1.25	94.3%	1.35	28.4%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow13.3 B $-7.0%

Capital Expenditures1.4 B $+14.2%

Free Cash Flow11.9 B $-9.0%

Dividends Paid-5.1 B $-203.3%

Peer Comparison· Drug Manufacturers - General

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
BMY	27.4%	24.6%	2.9%	182.9%
SAN	42.9%	34.1%	3.8%	192.2%
BAYN	10.0%	4.4%	5.5%	-209.8%
AZN	23.5%	14.5%	9.0%	136.9%
GRF	13.7%	10.1%	3.6%	246.1%
AZN	23.4%	12.7%	10.6%	136.0%
Industry median	23.7%	18.5%	5.3%	137.9%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
BMY	27.4%	24.6%	2.9%	182.9%
PFE	18.9%	15.0%	4.0%	160.0%
GILD	36.3%	34.4%	1.9%	117.3%
AMGN	28.9%	23.1%	5.8%	137.9%
MRK	27.3%	21.5%	5.8%	200.2%
BIIB	26.3%	26.6%	1.6%	188.8%
Industry median	23.7%	18.5%	5.3%	137.9%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on BMY

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 7, 26. This content is for informational purposes only and is not investment advice.